The nocebo effect in statin therapy: clinical implications for adherence and cardiovascular outcomes

Background Statins are foundational therapy for cardiovascular prevention; however, up to 50% of patients discontinue treatment within one year. Randomized trials show similar adverse event rates in statin and placebo groups, suggesting that nocebo effects contribute substantially to perceived intolerance and non-adherence. Objectives To evaluate the impact of statin-related nocebo effects on medication adherence, cardiovascular outcomes, and the effectiveness of mitigation strategies. Methods A scoping review was conducted across PubMed, Cochrane CENTRAL, Google Scholar, and ClinicalTrials.gov. Eligible studies included randomized controlled trials (RCTs), observational cohorts, qualitative studies, and systematic reviews of adults prescribed statins for primary or secondary prevention. Study quality was assessed using validated tools (Cochrane Risk of Bias, Newcastle–Ottawa Scale, AMSTAR-2). Evidence was synthesized according to PRISMA-ScR methodology using thematic analysis. Results Twenty-five studies (5 RCTs, 13 observational, 4 qualitative, 3 systematic reviews) comprising >3.2 million participants were included. N-of-1 trials demonstrated that ~90% of symptom burden during statin therapy was attributable to nocebo effects, with comparable symptoms during placebo phases. Among 37,668 placebo-treated participants, 42.6% reported statin-typical adverse effects without active drug exposure. Discontinuation patterns were frequently early and inconsistent with pharmacologic toxicity. High-intensity regimens showed reduced persistence despite non-proportional biological risk, supporting an expectation–dose relationship. Discontinuation within six months following myocardial infarction independently predicted increased all-cause mortality. Qualitative evidence highlighted clinician communication as a key determinant of expectations. Behavioral and cognitive interventions reduced nocebo responses and improved persistence. Conclusions A substantial proportion of statin-associated symptoms are mediated by nocebo mechanisms. Expectation-driven discontinuation is associated with increased cardiovascular risk. Targeted communication strategies and structured rechallenge approaches may improve adherence and reduce preventable cardiovascular events.